Dr. Pam Ventola, Senior Science Director at Cogstate, shares how the company is working to optimize brain health assessments in rare disease and pediatric clinical trials, and how this can help advance the development of new medicines and enable earlier clinical insights. She also discusses cognitive testing as part of decentralized trials, the role of central rating and central scoring, the development of indication-specific COAs for rare disease trials, and much more.
To find out more about Impetus: https://www.meetwithimpetus.com
Natalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/
Impetus Digital Website: https://www.impetusdigital.com/
Impetus Digital LinkedIn: https://www.linkedin.com/company/impetus-digital/
Impetus Digital Twitter: https://twitter.com/impetus_digital
Impetus YouTube: https://www.youtube.com/ImpetusDigital
Dr. Pam Ventola: https://www.linkedin.com/in/pam-ventola-222930105/
Cogstate: https://www.cogstate.com/
Impetus Digital has been delivering best-in-class virtual and hybrid meetings, events, and programs for global life science companies since 2008. We work closely with clinical, market access, medical affairs, marketing, medical education, and many other departments to virtualize their internal and external stakeholder meetings, such as advisory boards, learning programs, working groups, and congress engagement initiatives. We partner with clients at all stages of the product life cycle, from R&D to loss of exclusivity.
Click the social media buttons to share this episode with your network!
To learn more about Impetus, our services, and our tools: https://www.meetwithimpetus.com
Natalie Yeadon LinkedIn: https://www.linkedin.com/in/natalieyeadon/
Impetus Digital Website: Home Page
LinkedIn: https://www.linkedin.com/company/impetus-digital/
Twitter: impetus_digital
YouTube: Impetus Digital